AKR7A3 (aldo-keto reductase family 7 member A3) is a human enzyme that catalyzes NADPH-dependent reduction of carbonyl-containing compounds, including aldehydes and ketones 1. Its primary function involves detoxification of toxic metabolites, particularly aflatoxin B1 (AFB1) dialdehyde, which it reduces to less harmful alcohol derivatives via monoaldehyde intermediates 2. The enzyme demonstrates high catalytic efficiency with AFB1 dihydrodiol, with kinetic parameters comparable to other AFB1-metabolizing enzymes like cytochrome P450s and glutathione S-transferases 1. AKR7A3 shares 88% identity with human AKR7A2 and is expressed in liver and various extrahepatic tissues including stomach, pancreas, and kidney 1. Disease relevance includes its downregulation in gastric cancer and pancreatic ductal adenocarcinoma (PDAC), where reduced expression correlates with poor prognosis and increased metastasis 34. In PDAC, AKR7A3 inhibits progression by regulating PHGDH-mediated autophagy 4. Clinically, genetic polymorphisms in AKR7A3 (rs1738023/rs1738025) are associated with bleeding complications in elderly patients treated with rivaroxaban 5. The gene contains Nrf2 binding sites in its promoter, making it highly inducible by antioxidants 6. AKR7A3 represents a potential therapeutic target and prognostic marker for cancer treatment.